
Please try another search
(Reuters) - U.S. healthcare company Johnson & Johnson (N:JNJ) has approached Swiss biotechnology firm Actelion Ltd (S:ATLN) about a potential takeover, Bloomberg reported on Thursday, citing people it said were familiar with the matter.
The report said that deliberations are still at an early stage following Johnson & Johnson's initial offer, and Actelion is working with an adviser to explore options.
Johnson & Johnson Chief Executive Alex Gorsky said earlier this year that the company was interested in making deals to expand its main consumer, medical device, and pharmaceuticals segments. He noted that in recent years, J&J had derived about half its revenue from acquired products.
Johnson & Johnson agreed to buy Abbott Laboratories' (N:ABT) eye care business for about $4.33 billion in cash in September.
Actelion shares have risen more than 13 percent this year, valuing it at about $17 billion.
In October, Actelion raised its earnings guidance for the third time this year as sales from its new drugs Opsumit and Uptravi, which treat pulmonary arterial hypertension (PAH), for the first time surpassed those of Tracleer, its decade-long mainstay that lost U.S. patent protection last November.
Johnson & Johnson and Actelion were not immediately available for comment.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.